Kelman Lazarov Inc. lessened its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 9.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,953 shares of the company’s stock after selling 395 shares during the quarter. Kelman Lazarov Inc.’s holdings in Johnson & Johnson were worth $698,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently modified their holdings of the stock. Veracity Capital LLC boosted its stake in Johnson & Johnson by 1.2% in the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock worth $888,000 after purchasing an additional 59 shares during the period. Sandy Cove Advisors LLC raised its holdings in shares of Johnson & Johnson by 1.6% during the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock worth $605,000 after acquiring an additional 60 shares in the last quarter. LCM Capital Management Inc raised its holdings in shares of Johnson & Johnson by 0.7% during the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock worth $1,667,000 after acquiring an additional 61 shares in the last quarter. Arbor Investment Advisors LLC raised its holdings in shares of Johnson & Johnson by 2.3% during the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock worth $476,000 after acquiring an additional 61 shares in the last quarter. Finally, Mason & Associates Inc raised its holdings in shares of Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock worth $215,000 after acquiring an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Johnson & Johnson Stock Up 0.9 %
Shares of JNJ stock opened at $165.03 on Wednesday. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35. The stock has a market cap of $429.79 billion, a P/E ratio of 34.53, a P/E/G ratio of 2.78 and a beta of 0.53. The stock has a 50 day moving average of $158.00 and a 200 day moving average of $167.05. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.88%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 94.56%.
Analyst Ratings Changes
Several analysts recently weighed in on the company. Morgan Stanley increased their price target on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a report on Wednesday, April 19th. Atlantic Securities reduced their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 19th. UBS Group began coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price on the stock. Raymond James reduced their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 19th. Finally, SVB Leerink dropped their price target on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $173.00.
Insider Buying and Selling
In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is owned by company insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Do Bank Stocks Go Up When Interest Rates Rise?
- How to Invest in Vertical Farming Stocks
- Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
- Ecolab: Slow And Steady Wins The Race
- MGM’s Hot Hand Is All In For A Rally, After This Small Break
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
